Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus ...

Bell Potter has good things to say about this stock. The post Why this ASX 200 stock could jump 25% appeared first on The ...

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks. Read why ACAD stock is a buy.

Daybue would need to have a steady state treatment rate of 1,500-1,700 patients in the U.S. to reach $600-$700 million in annual net sales in the United States, based on an estimated net price per ...

In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE if significant weight loss occurs.

In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE if significant weight loss occurs.

SAN DIEGO, October 16, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...

Acadia Pharmaceuticals Inc. today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE ...

Daybue is supplied as a strawberry-flavored oral solution containing 200mg of trofinetide per mL. The dosage is determined by patient weight and can be administered orally or via gastrostomy tube.

Acadia Pharmaceuticals Inc. today announced that the journal Med published results from two open-label extension studies, LILAC-1™ and LILAC-2™, which showed that patients treated with DAYBUE ...